Tamborlane WV, Barrientos-Pérez M, Fainberg U, et al. - Through 135 patients who were 10 to less than 17 years of age, researchers assessed whether liraglutide added to metformin (with or without basal insulin treatment) was safe and efficient in youth with type 2 diabetes. The mean glycated hemoglobin level had declined with liraglutide and rose with placebo at the 26-week analysis of the primary efficiency endpoint. At both time points, the fasting plasma glucose level had declined in the liraglutide group but had rose in the placebo group. The overall rates of adverse events and gastrointestinal adverse events were greater with liraglutide. Thus, liraglutide, at a dose of up to 1.8 mg per day (added to metformin, with or without basal insulin), was efficient in enhancing glycemic control over 52 weeks, in children and adolescents with type 2 diabetes. Nevertheless, this effectiveness came at the cost of an heightened frequency of gastrointestinal adverse events.